PLR联合CHA<sub>2</sub>DS<sub>2</sub>-VASc评分对STEMI患者PCI术后发生无复流的预测价值

doi:10.3969/j.issn.1671-7171.2025.06.010

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1314 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the predictive value of the platelet-to-lymphocyte ratio (PLR) combined with the CHA₂DS₂-VASc score for the no-reflow phenomenon after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).【Methods】A total of 136 STEMI patients who underwent PCI were analyzed. According to the occurrence of the no-reflow phenomenon postoperatively, the patients were divided into groups. Binary logistic regression analysis was used to identify the influencing factors of reflow or no-reflow after PCI. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive value of PLR and CHA₂DS₂-VASc score for postoperative no-reflow.【Results】 Among the 136 patients, 31 cases (21.23%) developed the no-reflow phenomenon after PCI (no-reflow group), while the remaining 105 cases did not (reflow group). Preoperative systolic and diastolic blood pressure, interleukin-6, total stent length, PLR, and CHA₂DS₂-VASc score were all significantly higher in the no-reflow group compared to the reflow group (P<0.05). Logistic regression analysis showed that total stent length, PLR, and CHA₂DS₂-VASc score were risk factors for postoperative no-reflow. ROC curve analysis indicated that the combination of PLR and CHA₂DS₂-VASc score had a significantly higher area under the curve and specificity for predicting no-reflow after PCI compared to either parameter alone (P<0.05).【Conclusion】 The combination of PLR and CHA₂DS₂-VASc score has a high predictive value for the occurrence of no-reflow in STEMI patients after PCI and can serve as an important reference for evaluating postoperative no-reflow risk.

Key words： ST Elevation Myocardial Infarction Angioplasty, Balloon, Coronary Odds Ratio Lymphocytes Neutrophils No-Reflow Phenomenon

Received: 14 September 2024

PACS:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TAO Shoujian
	JIA Bei

Cite this article:

TAO Shoujian,JIA Bei. Predictive Value of PLR Combined with CHA₂DS₂-VASc Score for No-Reflow Phenomenon after PCI in STEMI Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 944-946.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.06.010 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I6/944

[1] 任月,田婷,韦光胜,等. Ⅰ期综合心脏康复对ST段抬高型心肌梗死急诊经皮冠状动脉介入术后患者的疗效[J].实用医学杂志,2024,40(5):682-687.
[2] 夏春,熊慧,戴文琴,等. 血清IL-17、Endocan及Nesfatin-1对ST段抬高型心肌梗死患者PCI术后无复流的预测价值[J].中国循证心血管医学杂志,2024,16(3):343-346.
[3] 邱崇荣,彭金亮,王萍,等. 急性心肌梗死患者PCI术前血清MMP-9、endocan水平与术后冠状动脉慢血流/无复流的相关性[J].医学理论与实践,2024,37(18):3175-3177.
[4] 刘闯,闫佩佩,陈雅丽,等. 急性心肌梗死患者NLR、LMR、PLR的表达及与PCI术后冠状动脉无复流的关系[J].中国循证心血管医学杂志,2023,15(5):616-618.
[5] 张嵚垚,胡美荣,孙佳莹,等. CHA₂DS₂-VASc评分对ST段抬高型心肌梗死患者直接PCI术后发生无复流和长期预后的预测价值[J].中国医科大学学报,2021,50(4):356-361.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.
[7] 张晶晶,朱华良,丁旵东,等. CHA₂DS₂-VASc评分对冠状动脉CTO患者PCI预后的预测价值[J].中国基层医药,2023,30(5):730-734.
[8] 潘颖洁,陈蕊,张玥,等. 急性ST段抬高型心肌梗死患者PCI术后无复流现象的研究进展[J].中南医学科学杂志,2021,49(3):358-362.
[9] 刘明,张阳阳,谭伟. 血清PAI-1、RBP4水平对急性ST段抬高型心肌梗死患者PCI后无复流的预测价值[J].山东医药,2023,63(16):22-25.
[10] 吴红丽,呼日乐巴特,孙洪涛,等. 基于冠状动脉造影术中即刻新型评分系统对STEMI患者急诊PCI术中慢血流/无复流的预测价值和短期预后研究[J].中国循证心血管医学杂志,2024,16(4):457-461.
[11] 吴树生,苏增锋. 青年STEMI患者急诊PCI术后无复流发生相关危险因素分析[J].现代科学仪器,2024,41(3):161-165.
[12] 高曼,白文楼,成思瑶,等. 院前负荷量替格瑞洛与氯吡格雷对转运PCI的急性STEMI患者术后慢血流/无复流及短期预后的影响[J].中国老年学杂志,2021,41(13):2689-2692.
[13] 赵轶超,刘洋洋,王文龙,等. 急性STEMI患者外周血miR-495表达水平与血常规炎症标志物的相关性及其与PCI术后无复流的关系[J].中国循证心血管医学杂志,2023,15(1):76-80.
[14] 吕思奇, 杨艳敏, 朱俊, 等. CHA₂DS₂-VASc评分对急性ST段抬高型心肌梗死患者近期预后的预测价值[J].中国循环杂志, 2021, 36(3):251-257.
[15] 陈飞, 鲁静朝, 杨秀春, 等. CHA₂DS₂-VASc评分对冠心病患者择期经皮冠状动脉介入治疗术后对比剂肾病的预测价值[J].中国循环杂志, 2018, 33(11):1049-1052.